Suppr超能文献

肝细胞癌患者肝功能的ALBI分级与Child-Pugh分级系统比较

ALBI versus Child-Pugh grading systems for liver function in patients with hepatocellular carcinoma.

作者信息

Na Seong K, Yim Sun Y, Suh Sang J, Jung Young K, Kim Ji H, Seo Yeon S, Yim Hyung J, Yeon Jong E, Byun Kwan S, Um Soon H

机构信息

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.

Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea.

出版信息

J Surg Oncol. 2018 Apr;117(5):912-921. doi: 10.1002/jso.24992. Epub 2018 Feb 15.

Abstract

BACKGROUND

The prognostic performance of the albumin-bilirubin (ALBI) grade in hepatocellular carcinoma (HCC) as an objective method of assessing liver function was investigated.

METHODS

Data from 2099 patients with HCC in Korea were collected and analyzed retrospectively. The discriminative performance of ALBI grade was compared with Child-Pugh (C-P) grade for different stages or treatments.

RESULTS

The median follow up duration was 16.2 months (range: 1.0-124.9). The median survival times were 49.7 months for C-P grade A (65.8%), 12.4 months for C-P grade B (25.5%), and 4.2 months for C-P grade C (8.6%) (P < 0.001). The median survival times were 84.2 months for ALBI grade 1 (32.8%), 25.5 months for ALBI grade 2 (53.5%), and 7.7 months for ALBI grade 3 (13.7%) (P < 0.001). In early UICC stages, ALBI grade showed better discriminative performance than C-P grade. In curative treatments, ALBI grade also showed better discriminative performance than C-P grade (Harrell's C: 0.624 (C-P grade) vs 0.667 [ALBI grade]).

CONCLUSIONS

ALBI grade provided better prognostic performance in survival analysis and better distribution of the grades than C-P grade in HCC, suggesting that ALBI grade could be a good alternative grading system for liver function in patients with HCC.

摘要

背景

研究了白蛋白-胆红素(ALBI)分级在肝细胞癌(HCC)中作为评估肝功能的客观方法的预后性能。

方法

回顾性收集并分析了韩国2099例HCC患者的数据。比较了不同分期或治疗情况下ALBI分级与Child-Pugh(C-P)分级的鉴别性能。

结果

中位随访时间为16.2个月(范围:1.0 - 124.9个月)。C-P A级患者的中位生存时间为49.7个月(65.8%),C-P B级为12.4个月(25.5%),C-P C级为4.2个月(8.6%)(P < 0.001)。ALBI 1级患者的中位生存时间为84.2个月(32.8%),ALBI 2级为25.5个月(53.5%),ALBI 3级为7.7个月(13.7%)(P < 0.001)。在国际抗癌联盟(UICC)早期阶段,ALBI分级的鉴别性能优于C-P分级。在根治性治疗中,ALBI分级的鉴别性能也优于C-P分级(Harrell氏C指数:0.624(C-P分级)对0.667 [ALBI分级])。

结论

在HCC患者中,ALBI分级在生存分析中提供了更好的预后性能,且分级分布比C-P分级更好,这表明ALBI分级可能是HCC患者肝功能的一个良好替代分级系统。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验